- Last Close 6.79
- Sector Healthcare
- Industry Biotechnology
- Investment Style Small Blend
- Day Range 6.67 – 7.02
- Year Range 5.53 – 14.97
- Market Cap 1.9605 Bil
- Volume / Avg 2.4 Mil / 2.1 Mil
- Price / Sales 11.59
- Price / Book 1.62
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis ABCL
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile ABCL
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Vancouver, BC, V5Y 0A1, CAN
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
AbCellera Biologics Inc Ordinary Shares
Vir Biotechnology Inc
SinoMab BioScience Ltd
Clene Inc Ordinary Shares
|$0.00 (0.00%)||+$0.40 (1.49%)||+$0.03 (1.67%)||−$0.01 (0.95%)|
|1.96 Bil||3.66 Bil||1.89 Bil||81.53 Mil|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for AbCellera Biologics Inc Ordinary Shares Stock
No. ABCL does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
ABCL’s market cap is 1.96 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
ABCL’s stock style is Mid Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
ABCL’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare ABCL’s historical performance against its industry peers and the overall market.